Bioject Medical Technologies Inc.: Two Separate Studies Presented at the AIDS Vaccine 2007 Conference Show Improved Results with the Biojector(R)2000

Published: Aug 22, 2007

PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today reported results from two studies presented at the AIDS Vaccine 2007 Conference in Seattle, Washington, which showed significantly improved results when the Biojector®2000 (“B2000”) needle-free system is used for the delivery of DNA vaccines.

Back to news